Chinese biotech start-ups are going up against Western drug makers - and they could win A decade ago, treating cancer with personalised mRNA vaccines seemed like a US$1 million gamble per patient, a ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

President Trump's proposed tariffs on Irish pharmaceutical imports aim to boost US production but may ultimately harm ...

Hyderabad: The National Company Law Tribunal has sanctioned the scheme of amalgamation between contract development and ...

THE TAOISEACH has said that “engagement is key” in the fallout of US President Donald Trump putting Ireland in the crosshairs ...

Proposed US tariffs on pharmaceutical exports will damage the economic prospects of US companies in Ireland, the Irish ...

BIG US pharma companies based in Ireland will be damaged by President Donald Trump’s tariffs, Taoiseach Micheal Martin has ...

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy ...

The global Analytical Standards Market, valued at US$1.44 billion in 2022, is forecasted to grow at a robust CAGR of 5.9%, reaching US$1.53 ...

As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...